Drug profile · INN
ritlecitinib
LITFULO
ritlecitinib (LITFULO) is a tyrosine-protein kinase jak3 inhibitor.
EMA: approved Antineoplastic and immunomodulating agents (L04) L04AF08
Patents linked 0
Pipeline programs 8
News articles 1
Drug details — ritlecitinib
- Class
- Antineoplastic and immunomodulating agents (L04)
- Route
- —
- Patents
- 0
- Programs
- 8
- Data quality
- 0.83
Quick answer
ritlecitinib (LITFULO) is a tyrosine-protein kinase jak3 inhibitor.
Key facts
INN ritlecitinib
Brand LITFULO
Mechanism Tyrosine-protein kinase JAK3 inhibitor
Target TEC family kinase
Therapeutic class Antineoplastic and immunomodulating agents (L04)
ATC code L04AF08
Mechanism of action
Tyrosine-protein kinase JAK3 inhibitor
Primary target: TEC family kinase
Approval history
| Authority | Status | Date |
|---|---|---|
| EMA | approved | — |
Recent coverage
Pipeline programs
Related & competitor drugs
Frequently asked questions
What is ritlecitinib?
ritlecitinib (LITFULO) is a tyrosine-protein kinase jak3 inhibitor.
What is the brand name for ritlecitinib?
LITFULO is a marketed brand name for ritlecitinib. Check FDA Drugs@FDA for the current US label holder and prescribing information.